Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Titel:
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Auteur:
Frias, Juan P Deenadayalan, Srikanth Erichsen, Lars Knop, Filip K Lingvay, Ildiko Macura, Stanislava Mathieu, Chantal Pedersen, Sue D Davies, Melanie